Journal of Asthma and Allergy (Jan 2020)
Profile of Baricitinib and Its Potential in the Treatment of Moderate to Severe Atopic Dermatitis: A Short Review on the Emerging Clinical Evidence
Abstract
Maddalena Napolitano,1 Gabriella Fabbrocini,2 Eleonora Cinelli,2 Luca Stingeni,3 Cataldo Patruno4 1Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy; 2Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 3Dermatology Section, Department of Medicine, University of Perugia, Perugia, Italy; 4Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, ItalyCorrespondence: Maddalena NapolitanoDepartment of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, ItalyTel +39 0817462439Email [email protected]: Atopic dermatitis (AD) is the most common chronic cutaneous inflammatory disease of childhood, affecting up to 25% of children; its prevalence in adulthood is currently unknown, since studies reported that AD may affect 0.3– 14.3% of adult population. In the last decade, the advanced understanding of AD molecular pathways along with patient’s and physician’s demand for more effective therapies, led to the introduction of new therapeutic agents. Baricitinib is an oral JAK inhibitor highly selective for JAK1 and JAK2. Treatment with baricitinib improved the signs and symptoms of moderate-to-severe AD compared to placebo, but it will be essential to better understand the safety profile of this drug.Keywords: baricitinib, adult atopic dermatitis, small molecules, JAK/STAT
